Perspective Therapeutics Inc. (CATX) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Perspective Therapeutics Inc. $0.66, price $2.62, upside -74.7%, quality 16 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Perspective Therapeutics Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $1.71 – $18.40 · fair‑value band $0.4335 – $0.8245 · the $2.62 price screens above the $0.6630 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow Perspective Therapeutics in your weekly email
Every Wednesday you see whether Perspective Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Show more
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Stock analysis
Perspective Therapeutics Inc. (CATX) currently trades at $2.62, while our model-based Fair Value estimate is $0.6630, implying the stock looks roughly 295.1% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.4335 (bear) to $0.8245 (bull), the price of $2.62 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Perspective Therapeutics Inc. reported revenue of $884K in FY2025 versus $10.1M in FY2021, a compound −45.5%/yr. Reported net income was −$103M in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −75%, CATX screens richer than that median.
Fair Value models
Bear $0.4335Fair Value $0.6630Bull $0.8245
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−39.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−56.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.0%
Start year 2020 (pandemic). Over 10 years: −15.2% a year
Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−35.9% (2020) → −12,846.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (62 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Perspective Therapeutics Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score22 · Bottom 25%
Fair Value upside−75% · Bottom 25%
Profitability
Return on assets−20% · Bottom 25%
Growth and dividend
Revenue growth−78% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B1.63× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 7
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Perspective Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/CATX
Frequently asked questions
Is Perspective Therapeutics Inc. (CATX) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.6630 versus a price of $2.62, about −75% upside (overvalued).
What is the fair value of CATX?
Our model-based fair value for Perspective Therapeutics Inc. is $0.6630 (as of Sep 23, 2026), built from audited fundamentals. The current price: $2.62.
What is the quality score of CATX?
Perspective Therapeutics Inc. has a Quality Score of 16/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Perspective Therapeutics Inc. (CATX)?
Our model-based price target is the fair value of $0.6630 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.4335, optimistic scenario $0.8245. It is a calculation from audited fundamentals, not an analyst target.
What is the Perspective Therapeutics Inc. stock forecast for 2026?
Our models put fair value at $0.6630, about −75% upside versus a price of $2.62 (overvalued). Cautious scenario $0.4335, optimistic scenario $0.8245. The calculation is refreshed regularly with new filings.
What is the revenue of Perspective Therapeutics Inc. (CATX)?
Perspective Therapeutics Inc. reported trailing-twelve-month revenue of about $618K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Perspective Therapeutics Inc. (CATX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Perspective Therapeutics Inc. it is $0.6630 per share (as of Sep 23, 2026), against a price of $2.62. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Perspective Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CATX trades above its calculated fair value: price $2.62, fair value $0.6630, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CATX?
No. The price is what the market pays today ($2.62); the fair value is what the company's own numbers justify ($0.6630). For Perspective Therapeutics Inc. the two are $1.96 per share apart. That gap is exactly why we show both numbers side by side.
How much is Perspective Therapeutics Inc. worth?
The market values Perspective Therapeutics Inc. at about $336M (market capitalisation, as of Sep 23, 2026). Per share that is $2.62; our models calculate a fair value of $0.6630 per share.
What do the bullish and bearish scenarios say about CATX?
Our models span a range for Perspective Therapeutics Inc.: cautious scenario $0.4335, base $0.6630, optimistic $0.8245 per share (as of Sep 23, 2026, price $2.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Perspective Therapeutics Inc. (CATX)?
Balance-sheet figures for Perspective Therapeutics Inc. (as of Sep 23, 2026): return on equity −35.3%, debt of 0.01 per unit of equity. They feed the Quality Score of 16/100, which measures business quality independently of the share price.
How far is CATX from its 52-week high?
Perspective Therapeutics Inc. trades at $2.62, about 54% below its 52-week high of $5.65 and 28% above the low of $2.05 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6630 is for.
Which stocks are comparable to Perspective Therapeutics Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Perspective Therapeutics Inc. stock attractive at the current price?
The data as of Sep 23, 2026: price $2.62, calculated fair value $0.6630 (−75%), Quality Score 16/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CATX calculated?
We run Perspective Therapeutics Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6630, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Perspective Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Perspective Therapeutics Inc. (CATX)?
The closing price on Sep 23, 2026 was $2.62. Our model-based fair value is $0.6630, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Perspective Therapeutics Inc. right now?
The price sits above even our optimistic bull case ($0.8245). The favourable scenario is already priced in. Weak quality (16/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.4335 to $0.8245) leaves room in how you read the outcome.
Key figures of Perspective Therapeutics Inc.
How large is the market capitalisation of Perspective Therapeutics Inc. (CATX)?
The market capitalisation of Perspective Therapeutics Inc. is $336M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Perspective Therapeutics Inc. (CATX)?
Earnings per share at Perspective Therapeutics Inc. are $−1.41. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Perspective Therapeutics Inc. (CATX)?
The return on equity (ROE) of Perspective Therapeutics Inc. is −35.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Perspective Therapeutics Inc. (CATX)?
On an EBIT basis the return on assets of Perspective Therapeutics Inc. is −16.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Perspective Therapeutics Inc. (CATX)?
The operating margin of Perspective Therapeutics Inc. is −37,212% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Perspective Therapeutics Inc. (CATX)?
Revenue at Perspective Therapeutics Inc. is growing −77.8% versus a year earlier (3y avg −56.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Perspective Therapeutics Inc. (CATX) generate?
The free cash flow of Perspective Therapeutics Inc. is −$95.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Perspective Therapeutics Inc. (CATX) hold?
Perspective Therapeutics Inc. holds more cash than debt, $29.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Perspective Therapeutics Inc. in the live analysis
One click puts Perspective Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026